[Practical applications of recombinant alpha-1-antitrypsin in medicine].

Abstract

Alpha-1-antytripsin deficiency, human plasma protein belonging to serine proteinase inhibitor, is the underlying reason for causing such diseases as liver cirrhosis or pulmonary emphysema. It has been proven that alpha-1-antytripsin deficiency can be treated with replacement therapy of this protein. Because of the risks associated with the administration to patients with deficiency of alpha-1-antytrypsyny protein fractionated from human plasma, the methods of gaining recombinant alpha-1-antytripsin are still being developed. Methods for the production of alpha-1-antytripsin synthesized using transgenic animals can achieve high performance while maintaining a fully functional protein structure. Obtained in this way, alpha-1-antitrypsin gives hope for the use of replacement therapy on a large scale.

• Authors: Jacek Kabziński, Józef Kedziora, Ireneusz Majsterek
• Journal: Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego (Pol Merkur Lekarski) Vol. 29 Issue 174 Pg. 345-50 (Dec 2010) ISSN: 1426-9686 [Print] Poland
• Vernacular Title: Zastosowania rekombinowanej alfa-1-antytrypsyny w terapil medycznej.
• PMID: 21298982 (Publication Type: Editorial, English Abstract)

Chemical References

• Recombinant Proteins
• alpha 1-Antitrypsin

Topics

• Animals
• Animals, Genetically Modified
• Humans
• Liver Cirrhosis (drug therapy, etiology)
• Pulmonary Emphysema (drug therapy, etiology)
• Recombinant Proteins (therapeutic use)
• alpha 1-Antitrypsin (therapeutic use)
• alpha 1-Antitrypsin Deficiency (complications, drug therapy)